Repare Therapeutics Raises US$82.5M in Series B Financing

cancerRepare Therapeutics, a St-Laurent, Quebec, Canada and Cambridge, MA-based precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, completed a US$82.5m Series B financing.

The round was led by Cowen Healthcare Investments joined by new investors OrbiMed, Redmile, BVF Partners L.P. and Logos Capital. Founding investor Versant Ventures and existing investors MPM Capital, Fonds de solidarité FTQ, and BDC Capital all participated. In conjunction with the funding, Kevin Raidy, Managing Partner, Cowen Healthcare Investments, and David Bonita, M.D., Partner, OrbiMed, will join Repare’s Board of Directors.
Including this Series B financing and the June 2017 Series A round co-led by Versant and MPM, Repare has now secured over US$140m in equity and partner capital.

The company intends to use the funds to advance its pipeline of synthetic-lethal, precision oncology therapies for multiple solid tumor indications and bring them to clinic in the next 18 months.

Led by Lloyd M. Segal, President and Chief Executive Officer, Repare is pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations. The company’s initial focus is on novel targeted therapies in cancer types harboring defective DNA-damage response (DDR)- or genome instability-related functions. Its SNIPRx™ platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery technology with high‐resolution protein crystallography, computational biology, medicinal chemistry and clinical informatics to rapidly generate small molecules for clinical investigation.

The company will advance:

  • RP-3500, an ATR inhibitor, into the clinic in 2020,
  • “Manchester”, an undisclosed CCNE1 synthetic lethal targeted therapy, in the subsequent two to three quarters, and
  • its deep pipeline of synthetic lethal, DNA damage repair programs, including its Polθ program, which was recently partnered with ONO Pharmaceutical Co., Ltd. in Japan and selected territories in Asia.



Join the discussion